Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
17/06/2025 24:42
June 16 (Reuters) - Eli Lilly LLY.N is in advanced talks to acquire gene editing startup Verve Therapeutics VERV.O for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter. Reuters could not immediately verify the report. (Reporting by Ananya Palyekar in Bengaluru; Editing by Alan Barona) ((Ananya.Palyekar@thomsonreuters.com))